Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study

被引：1

作者：

Boersma, C

Carides, GW

Burke, TA

Postma, MJ

机构：

[1] Univ Groningen, Groningen, Netherlands

[2] Merck Res Labs, Blue Bell, PA USA

[3] Merck & Co Inc, Whitehouse Stn, NJ USA

来源：

VALUE IN HEALTH | 2005年 / 8卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)67611-5

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A150 / A151

页数：2

共 50 条

[1] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study
Boersma, C.
Carides, G. W.
Postma, M. J.
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 720 - 721
[2] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation of the LIFE trial
Jonsson, B
Carides, GW
Burke, TA
Dasbach, EJ
Lindholm, L
Dahlof, B
[J]. JOURNAL OF HYPERTENSION, 2004, 22 : S289 - S290
[3] Cost-effectiveness of losartan in patients with hypertension and LVH in Spain: An economic evaluation based on the life trial
Ruilope, LM
Burke, TA
Carides, GW
Nocea, G
[J]. VALUE IN HEALTH, 2004, 7 (06) : 689 - 689
[4] Cost effectiveness of losartan in patients with hypertension and LVH:: an economic evaluation for Sweden of the LIFE trial
Jönsson, B
Carides, GW
Burke, TA
Dasbach, LJ
Lindholm, LH
Dahlöf, B
[J]. JOURNAL OF HYPERTENSION, 2005, 23 (07) : 1425 - 1431
[5] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
McInnes, G
Burke, TA
Carides, G
[J]. JOURNAL OF HUMAN HYPERTENSION, 2006, 20 (01) : 51 - 58
[6] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
G McInnes
T A Burke
G Carides
[J]. Journal of Human Hypertension, 2006, 20 : 51 - 58
[7] An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Ye Seol Lee
Hae-Young Lee
Tae Hyun Kim
[J]. Clinical Hypertension, 28
[8] An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Lee, Ye Seol
Lee, Hae-Young
Kim, Tae Hyun
[J]. CLINICAL HYPERTENSION, 2022, 28 (01)
[9] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
Ekman, M.
Bienfait-Beuzon, C.
Jackson, J.
[J]. JOURNAL OF HUMAN HYPERTENSION, 2008, 22 (12) : 845 - 855
[10] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
M Ekman
C Bienfait-Beuzon
J Jackson
[J]. Journal of Human Hypertension, 2008, 22 : 845 - 855

← 1 2 3 4 5 →